abs95.txt	although	anti-pd-1	therapy	has	improved	clinical	outcomes	for	select	patientswith	advanced	cancer		many	patients	exhibit	either	primary	or	adaptive	resistanceto	checkpoint	inhibitor	immunotherapy	the	role	of	tumor	stroma	in	thedevelopment	these	mechanisms	resistance	to	inhibitors	remainsunclear	we	demonstrated	that	pharmacologic	inhibition	tgfβ	signalingpathway	synergistically	enhanced	efficacy	anti-ctla-4	butfailed	augment	anti-pd-1/pd-l1	responses	an	autochthonous	model	ofbrafv600e	melanoma	additional	mechanistic	studies	revealed	pathwayinhibition	promoted	proliferative	expansion	stromal	fibroblasts	therebyfacilitating	mmp-9-dependent	cleavage	pd-l1	surface	expression	leading	toanti-pd-1	this	further	work	melanomasescaping	exhibited	a	mesenchymal	phenotype	associated	withenhanced	signaling	activity	delayed	followinganti-pd-1	escape	better	served	control	disease	progression	and	wassuperior	continuous	combination	workillustrates	formulating	regimens	enhance	theefficacy	blockade	requires	in-depth	understanding	impactof	agents	on	microenvironment	data	indicated	stromalfibroblast	mmp-9	may	desensitize	tumors	suggests	tgfβinhibition	generate	greater	immunologic	when	administered	followingthe	development	acquired	immunol	res	1-13	©2018aacr
